[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Life Sciences Market Research Reports & Industry Analysis

“Life sciences” is a common name of a raft of sciences dealing with living organisms and various types of life processes. The life sciences industry can be divided into several sub-groups such as Biotech & Pharma, healthcare, medical devices, research and lab services. Pharmaceuticals form the largest market sector; its sales are predicted to override USD 1 trillion by 2015.

The life sciences market proved to be rather resistant to unfavorable economic conditions. It has experienced healthy growth over the recent years on the back of the population increase, ongoing technological advancements and rising awareness of healthcare. Drug discovery, medical equipment and regenerative medicine represent the most promising market sectors.

A wealthy collection of the research reports providing extensive overview of the life sciences market is at hand in this MarketPublishers’ catalogue. Current situation and historic development of the market are reviewed in the researches. The reports thoroughly examine market segments, disclose essential information on the market size and characterize the industry dynamics and identify major forces shaping the market. Moreover, the long-term and short-term future outlooks for the market can be found in the research reports.

Publications found: 253,269
Sort by:

Underappreciated Megablockbuster Drug Patent Expiry Opportunities for API Manufacturers and Generic Drug Companies

US$ 2,000.00

2012 presented a bonanza for generic and API companies, as products worth $50b have seen the entry of generic competition. A select few companies which planned much in advance for these patent expirie...

February 2012 30 pages

Cancer Monoclonal Antibodies Market to 2015

US$ 1,500.00

Globally, cancer is one of the leading causes of death, and accounted for almost 13% of total deaths in 2008. The cases of lung and breast cancers are expected to grow rapidly in the coming years. In...

February 2012 105 pages

Global Biosimilars Market Forecast to 2015

US$ 1,500.00

The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid po...

February 2012 140 pages

Indian Hospital Services Market Outlook

US$ 800.00

The hospital services’ market represents one of the most lucrative segments of the Indian healthcare industry. Various factors, such as increasing prevalence of diseases, improving affordability, and...

February 2012 100 pages

Engaging KOLs: new thinking on thought leader development

US$ 595.00

Key opinion leaders (KOLs) play a vital role in the effective development and marketing of drugs and medical devices. However, restrictions are increasingly being imposed on the ways in which...

February 2012 58 pages

Generic Defence Strategies: Targeting Patient Co-Pay

US$ 695.00

Coupons for co-pays are fast becoming a standard part of the brand marketer’s toolkit, due to proven positive ROI. It’s projected that by 2017, coupons will be associated with 30% of all U.S. prescrip...

February 2012 41 pages

New Thinking in Patient Adherence

US$ 695.00

Patient non-adherence is estimated to represent $290 billion per year in avoidable medical expenses in the United States alone. Consumers’ motivations for non-compliance are complex; up to 80% of peop...

February 2012 62 pages

U.S. Market for Pediatric Guided Growth Systems

US$ 2,995.00

... had been the gold standard for treating angular deformities; however, pediatric guided growth systems (PGGS) are quickly gaining popularity. Various deformities ... and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report ...

February 2012 11 pages

Bristol-Myers Squibb - Eliquis: FDA Decision Date Extended by Three Months

US$ 90.00

... BMY, the USFDA has extended the review period for Eliquis by 3 months (new PDUFA June 28th). At this ... has not announced any advisory committee to discuss Eliquis approval, but one may not rule out ... concerns over safety of Dabigatran. This delay in Eliquis approval, will obviously give some additional time for ...

February 2012 2 pages

Medicated Skin Care in China

US$ 990.00

Medicated skin care is one of the most important OTC categories in China, with sales value reaching RMB7.7 billion in 2011, up by 11% from 2010. ... rural areas in China, coupled with negative environmental factors, drove medicated skin care sales over the review period. Euromonitor International's Medicated Skin Care in China report offers a comprehensive ...

February 2012 49 pages

Dainippon Sumitomo - Acquiring Boston Biomedical - Hitting Two Birds with One Stone!

US$ 90.00

Dainippon Sumitomo Pharma (DSP) makes a major strategic move by acquiring Boston Biomedical for $200m upfront payment. At first sight, DSP acquires an advanced onco thx platform along ...

February 2012 3 pages

GALAPAGOS - Santa Arrives – Late but With Bounty!

US$ 90.00

Today’s exclusive global agreement of Galapagos’ (GLPG) GLPG0634 (PhII, RA, oral JAK1 inhibitor) with a veteran player in ... , please read our report released on 29th February on GLPG titled “Santa Arrives – Late but With Bounty!”

February 2012 3 pages

Medicated Skin Care in Canada

US$ 990.00

... with their day-to-day health concerns. Additionally, a... Euromonitor International's Medicated Skin Care in Canada report offers a comprehensive guide to the size and shape of the ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...

February 2012 34 pages

Medicated Skin Care in Chile

US$ 990.00

... in 2010 was the highest in the review period. Euromonitor International's Medicated Skin Care in Chile report offers a comprehensive guide to the size and shape of the ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...

February 2012 27 pages

INCYTE: Testing Time Ahead For JAKAFI

US$ 140.00

While the commercial challenge for Incyte (INCY) in US has just begun (reported only $2m net sales since ... , please read our report released on February 28, 2012 on INCY, titled “Testing Time Ahead For JAKAFI”.

February 2012 3 pages

TAKEDA - TAK-875 Data in ‘The Lancet’ - First GPR-40 Can Potentially Alter Diabetes Therapy Paradigm, Though a Few Questions Remain Unanswered!

US$ 300.00

... refractory patients– each of these segments carries ~$1b opportunity to Takeda. In this report, we have analyze TAK-875 market positioning and model, target segments, therapy ...

February 2012 10 pages

Emerging Hemostasis Diagnostic Tests and Suppliers Developing New Technologies and Products

US$ 1,480.00

This 125-page report presents an overview of the clinical significance and market needs for major hemostasis laboratory tests, as well as extensive listings of companies developing or marketing hemostasis technologies and products. Contains 125 pages and 20 tables

February 2012 125 pages

Hemostasis Diagnostics Market Leading Suppliers and Emerging Market Entrants

US$ 2,000.00

This report presents analyses of major current and emerging suppliers of hemostasis products, including: The 2010 sales estimates Market shares Product portfolios Marketing tactics Technological know-how New products in R&D Collaborative arrangements Business strategies. Contains 45 pages

February 2012 45 pages

Japan- Pharma Fact Sheet

US$ 400.00

Looking at the great deal of business interest in the Japan Pharmaceutical space, we have recently published a report on Japan Pharma - "Japan Pharma - Factsheet". The 10 page report has som...

February 2012 8 pages

DAIICHI SANKYO - Growth Story Remains Intact!

US$ 90.00

... rating on Daiichi Sankyo (DS) while revising down 12-months TP to ¥1,850 on account of incorporating likely impact of Ranbaxy settlement cost and tax reforms in Japan. Going forward ...

February 2012 2 pages

FDA Accepts ACTEMRA sBLA for 1st- Line – A Step Closer Towards Approaching Full Market Potential!

US$ 90.00

FDA accepted Actemra’s application for 1st-line biologic for RA patients. The development brings Actemra a step closer to its likely full market potential where it ... and approval as SC formulation are also crucial in determining sales ramp of Actemra and are due by 1H 2012 and 2014 respectively. We see a fair ...

February 2012 3 pages

RANBAXY - Teva Partnership Hurts

US$ 140.00

... the unexpectedly high payment of ~$150m to Teva under the Lipitor generic agreement. Ranbaxy generated ~$300m from generic Lipitor that ... (1) Daiichi-Ranbaxy likely to become the largest generic company in Japan generics market (2) leveraging of Ranbaxy’s emerging market infrastructure (especially India) to ...

February 2012 6 pages

VIVUS: Potential for Adding More Weight in April

US$ 140.00

... safety profile. With the risk of generics, commercial potential of Avanafil worth... The upside could be more in case of a buyout, favorable licensing deal, ... approval time in April… For more details, please read our report released on February 24, 2012 on VVUS, titled “Potential for Adding More Weight in April”

February 2012 9 pages

Assessment of the Asia-Pacific In-Vitro Diagnostic (IVD) Market

US$ 800.00

... the healthcare facilities. The segments expected to witness high growth in the Asia IVD market are molecular diagnostics, point-of-care tests and self ... issues. Why should the report be purchased? Our report ‘Assessment of the Asia-Pacific In-Vitro Diagnostic (IVD) Market’ provides an overview of the IVD ...

February 2012 25 pages

Life Science & Chemical Instrumentation Market (2011 - 2016) Global Trends, End User & Competitive Analysis

US$ 5,650.00

... require quality instruments with high throughput capacity. All these factors are driving the life science and chemical instrumentation market. The global life science and chemical instrumentation market ... Life science and chemical instruments instrumentation market, by end-users: Pharmaceuticals and biopharmaceutical companies Research laboratories Academic institution Food and beverages Environmental Others Life science and chemical instruments instrumentation ...

February 2012 391 pages

Medicated Skin Care in Australia

US$ 990.00

Value growth of 4% in medicated skin care in 2011 was largely generated by changes in Australia’s demographic mix, particularly in relation to age. Succinctly, growth was driven by ... grew by 8%, making nappy rash the fastest growing niche in medicated skin care. Euromonitor International's Medicated Skin Care in Australia report offers a comprehensive guide to the size and shape ...

February 2012 34 pages

Indian Healthcare Sector - Performance & Ranking Review (December 2011)

US$ 300.00

Executive summary This report provides the periodic review of Healthcare sector index and ranking. In today’s dynamic business world, indices play a vital role within the investment process...

February 2012 49 pages

China’s Guidebook for Pharmaceutical Patent Protection

US$ 1,495.00

Description China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB 1550 billion (about US...

February 2012 230 pages

Emerging Special Hematology Tests and Flow Cytometry Applications

US$ 1,480.00

The report presents an overview of the clinical significance and market needs for major hematology and flow cytometry procedures, including listings of companies developing or marketing new technologies and products. Contains 85 pages

February 2012 85 pages

Medicated Skin Care in Indonesia

US$ 990.00

... awareness of the presence of some medicated skin care products to treat their conditions in the first place. Euromonitor International's Medicated Skin Care in Indonesia report offers a comprehensive guide to the ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...

February 2012 35 pages

REGENERON: Marching Towards Profitability!

US$ 140.00

... Lucentis)! REGN should finally evolve from a Rising Star to become a profitable Biotech from 2012 onwards on the strength of its pipeline and ... , please read our report released on February 17, 2012 on REGN, titled “Marching Towards Profitability!”

February 2012 8 pages

Medicated Skin Care in Azerbaijan

US$ 990.00

... within this area. Consequently, many consumers began to use medicated skin... Euromonitor International's Medicated Skin Care in Azerbaijan report offers a comprehensive guide to the size and shape ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...

February 2012 28 pages

Flow Cytometry Instrumentation Review: Operating Characteristics, Features and Selling Prices of Leading Analyzers

US$ 1,480.00

This report reviews current instrumentation technologies, and compares features of leading flow cytometry analyzers. Contains 14 pages

February 2012 14 pages

Medicated Skin Care in Uruguay

US$ 990.00

... medicated skin care products at a good and steady pace, producing sustained growth in volume and value sales across most of the category. Euromonitor International's Medicated Skin Care in Uruguay ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...

February 2012 21 pages

Medicated Skin Care in Israel

US$ 990.00

... to strict regulations. Companies in Israel have recently realised the strong potential among the more profitable medical devices within medicated skin care products. There are many different products within medicated skin care. Lice treatment, for example, is highly influenced by sales of medical devices. Euromonitor International's Medicated Skin Care in Israel ...

February 2012 33 pages

Medicated Skin Care in Peru

US$ 990.00

... -income consumers. Despite this, generics are progressively... Euromonitor International's Medicated Skin Care in Peru report offers a comprehensive guide to the size and shape of the ... and Allergy Remedies, Paediatric Digestive Remedies, Paediatric Medicated Skin Care, Pharyngeal Preparations, Standard Eye Care, Sticking Plasters/Adhesive Bandages, Systemic Analgesics, Topical ...

February 2012 34 pages

The Heathcare Payor BPO Landscape in 2011: Will Reform Shatter a Complacent Industry?

US$ 500.00

This industry analysis report, co-authored with HfS, examines the key business challenges faced by the global pharmaceuticals industry and the resulting impact of outsourcing within this segment. This...

February 2012 44 pages

Future Nucleic Acid Testing Market - New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers

US$ 22,800.00

... -country, 1,050-page report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the ... during this decade. Highlights Business and technological trends in seven major markets Five- and ten-year test volume and sales forecasts ...

February 2012 1050 pages

Tumor Marker Testing Instrumentation: Operating Characteristics, Features and Selling Prices of Leading Automated and Semi-Automated Analyzers

US$ 760.00

This report reviews current instrumentation technologies, and compares features of major automated and semi-automated analyzers used for tumor marker testing. Contains 25 pages

February 2012 25 pages

Emerging Opportunities in Cancer Nucleic Acid Testing

US$ 1,160.00

The report presents an overview of the clinical significance and market needs for major tumor markers, as well as listings of companies developing and marketing NAT technologies and products for cancer testing. Contains 45 pages

February 2012 45 pages

Future Infectious Disease Nucleic Acid Testing

US$ 2,000.00

This 360-page report presents an overview of the clinical significance and market needs for major infectious diseases, as well as extensive listings of companies developing and marketing molecular diagnostic technologies and products. Contains 360 pages and 20 tables

February 2012 360 pages

Tumor Marker Testing: A Global Overview - Facilities, Test Volumes, and Sales Forecasts by Country

US$ 760.00

This report provides: Worldwide overview of the tumor marker diagnostics market Mortality statistics and scientific views on the etiology of major types of cancer. Estimates of the number of laboratories performing tumor marker testing. Ten-year test volume and sales forecasts by country. Contains ...

February 2012 11 pages

Tumor Marker Diagnostic Technologies and Their Potential Market Applications

US$ 1,480.00

... potential applications of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry and biosensors or tumor marker diagnostic testing. Review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy. Contains 110 pages

February 2012 110 pages

Future French Tumor Marker Testing Market Outlook

US$ 4,320.00

... Comprehensive 585-page analysis of the French tumor marker testing market. Major issues pertaining to the French laboratory practice, as well as key ... volume and sales forecasts for over 40 tumor markers performed in French hospitals and commercial laboratories. Placements and installed base of automated ...

February 2012 585 pages

Future German Tumor Marker Testing Market Outlook

US$ 4,320.00

... Comprehensive 585-page analysis of the German tumor marker testing market. Major issues pertaining to the German laboratory practice, as well as key ... volume and sales forecasts over for 40 tumor marker performed in German hospitals, commercial laboratories and physician offices. Placements and installed ...

February 2012 585 pages

Future Italian Tumor Marker Testing Market Outlook

US$ 4,320.00

... Comprehensive 570-page analysis of the Italian tumor marker testing market. Major issues pertaining to the Italian laboratory practice, as well as key ... volume and sales forecasts for over 40 tumor marker performed in Italian hospitals and commercial laboratories. Placements and installed base of automated ...

February 2012 570 pages

Future Japanese Tumor Marker Testing Market Outlook

US$ 5,360.00

Highlights Comprehensive 590-page analysis of the Japanese tumor marker testing market. Major issues pertaining to the Japanese laboratory practice, as well as key ... , lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ...

February 2012 590 pages

Future Spanish Tumor Marker Testing Market Outlook

US$ 4,320.00

Highlights Comprehensive 565-page analysis of the Spanish tumor marker testing market. Major issues pertaining to the Spanish laboratory practice, as well as key ... , lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for 40 ...

February 2012 565 pages

Future UK Tumor Marker Testing Market Outlook

US$ 4,320.00

... leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ... base of automated and semi-automated analyzers used for tumor marker testing. Current instrumentation technologies and feature comparison of leading analyzers. ...

February 2012 575 pages

Future US Tumor Marker Testing Market Outlook

US$ 6,960.00

... leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for ... base of automated and semi-automated analyzers used for tumor marker testing. Current instrumentation technologies and feature comparison of leading analyzers. ...

February 2012 620 pages

Filters

Search

Categories

57
23,521
370
94
999
914
541
405
240
22
8,559
251
675
84
1,065
4
507
19
241
547
553
305
23
177
39
33,609
40
139
353
702
23
152
69
5,333
95
1,835
167
48
819
116
1,162
657
549
1,866
4,252
1,146
70
110,523
509
48,729
94

Publishers

251
21
1
4
204
62
262
243
2
922
79
698
53
68
583
106
6,695
6,889
30,350
501
2,483
5,841
1
3
1
1
484
7
1,083
7,751
450
142
448
1
2,189
1
136
9
1,696
8
29
79
6
2
75
11,736
2,426
698
6
10,807
171
1
321
1,034
1
33,621
484
66
5
5
214
2
1,360
5,811
151
56
481
149
148
214
3,604
3
4
536
197
15
23
3
107
22
19,652
31
31
1
16
89
9,602
54
143
74
807
1
1,261
2,133
48
220
29
5
11,194
2
45
173
10
108
5
482
11
33
21
160
348
36
110
436
2
89
186
8
313
5
3
386
4
118
58
53
61
8
20
120
111
2
9
1
1,866
1
13
10
5
492
1
1
15
1
38
2
3
28
7
3
1
207
7
1
306
6
368
3
280
51
43,810
140
1
2
4
114
2
16
9
43
26
1
212
3
9
4
22
1
2,327
3,738
1
2
3
220
400
78
689
970
388
206
160
8
47
32
328
38
4
1,155
7

Regions

247
231
217
215
215
200
198
197
196
156
154
140
140
140
136
136
131
19
18
17
17
15
11
10
7
6
5
5
4
4
3
3
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
256
39
158
6,398
1,652
1,545
1,417
1,384
1,367
1,363
346
330
310
300
298
288
287
283
276
274
274
274
273
272
271
268
267
267
266
265
265
264
261
261
260
259
255
254
254
253
252
249
242
232
226
226
221
203
196
190
190
181
161
151
67
36
33
26
14
2
134
131
5,387
317
287
281
7,450
3,586
412
198
114
182,781
208
191
195
474
472
296
290
267
249
155
175
32
238
173
163
155
236
193
17
143
32
238
36
4,814
4,304
8,010

Price

Date

Pages

Offers

257
112
1
384
7
5
17